32211 Beyond PSA: Molecular Markers of Prostate Cancer

Member Price: $0.00
Non-Member Price: $0.00

Your Price:

$0.00



 

Afternoon Symposium


James Faix, MD, Stanford University, Palo Alto, CA
College of American Pathologists, Clinical Translational Science Division


PSA screening for prostate cancer is controversial, and PSA levels do not help to establish the likelihood of aggressive tumor behavior. This session will review our current understanding of the molecular pathogenesis of cancer. Using prostate cancer as a model, speakers will also illustrate the potential for molecular markers of both genetic abnormalities and viral infection to diagnosis and management.